RecruitingNot ApplicableNCT06728462

A Study of Amorphous Calcium Carbonate in Postmenopausal Women

A Study Benchmarking FREEDOM Substudy to Evaluate the Effects of Amorphous Calcium Carbonate in Postmenopausal Women

Sponsor

Universal Integrated Corp.

Enrollment

205 participants

Start Date

Mar 4, 2025

Study Type

INTERVENTIONAL

Conditions

bone mineral density Osteoporosis Calcium Bone Turnover Marker Denosumab

Summary

Using the FREEDOM substudy as a benchmark, evaluate the effects of amorphous calcium carbonate (ACC) on bone mineral density (BMD) in postmenopausal women, both with and without the combination of Denosumab treatment.

Eligibility

Sex: FEMALEMin Age: 60 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Amorphous calcium carbonate for people with bone turnover marker, calcium, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 60 Years to 90 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.